Efficacy, safety and tolerability of switching from GLP-1RA to maridebart cafraglutide in adults with obesity or overweight.
- Investigator
- Diana Barb
- Status
- Accepting Candidates
- Ages
- 18 Years - 99 Years
- Sexes
- All
Diana Barb, MD
Endocrinologist (Diabetes & Hormones Specialist)
Rated
4.7
out of 5 stars
Research at a glance
Top areas of exploration
- Diabetes Mellitus, Type 2 , 20 publications
- Non-alcoholic Fatty Liver Disease , 19 publications
- Insulin Resistance , 12 publications
- Liver , 12 publications
Research activity
Active clinical trials
My publications
Filter publications
47 publications
2026
High Prevalence of Metabolic Dysfunction-Associated Steatohepatitis With Significant Fibrosis in Primary Care and Endocrinology Clinics.
Diabetes, obesity & metabolism
PubMed • Publisher's site2026
Severity of MASH activity by iron-corrected MRI predicts insulin resistance and cardiometabolic risk in type 2 diabetes.
The Journal of clinical endocrinology and metabolism
PubMed • Publisher's site2026
PPARidgm shifts in the treatment of metabolic dysfunction-associated steatotic liver disease.
Hepatology (Baltimore, Md.)
PubMed • Publisher's site2026
Evaluation of a conversation aid for patients with thyroid nodules considering a biopsy: pilot multicenter randomized control trial.
Endocrine
PubMed • Publisher's site2026
Improving MASLD Risk Stratification in Young Adults with Cardiometabolic Risk Factors and Insulin Resistance Assessment.
Journal of the Endocrine Society
PubMed • Publisher's site